Versant Venture Capital VI, L.P. 13D and 13G filings for Monte Rosa Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-10-30 5:10 pm Sale | 2024-10-28 | 13D | Monte Rosa Therapeutics, Inc. GLUE | Versant Venture Capital VI, L.P. | 4,079,469 6.600% | -1,019,867 (-20.00%) | Filing |
| 2024-09-24 5:00 pm Sale | 2024-09-20 | 13D | Monte Rosa Therapeutics, Inc. GLUE | Versant Venture Capital VI, L.P. | 5,099,336 8.300% | -1,699,779 (-25.00%) | Filing |
| 2024-08-12 5:07 pm Unchanged | 2024-08-08 | 13D | Monte Rosa Therapeutics, Inc. GLUE | Versant Venture Capital VI, L.P. | 6,799,115 11.100% | 0 (Unchanged) | Filing |
| 2023-11-09 5:26 pm Unchanged | 2023-08-10 | 13D | Monte Rosa Therapeutics, Inc. GLUE | Versant Venture Capital VI, L.P. | 6,799,115 13.700% | 0 (Unchanged) | Filing |
| 2021-07-08 4:31 pm Purchase | 2021-06-28 | 13D | Monte Rosa Therapeutics, Inc. GLUE | Versant Venture Capital VI, L.P. | 6,799,115 15.300% | 6,799,115 (New Position) | Filing |